Owens & Minor price target raised to $28 from $24 at Baird

Baird analyst Eric Coldwell raised the firm’s price target on Owens & Minor to $28 from $24 and keeps a Neutral rating on the shares. The firm said they expect continued Patient Direct strength and potential PHS normalization in 2024, with earnings building through year. Baird said after the recent rally, valuationcurrently appears less attractive.